Equillium, Inc.
Equillium, Inc. EQ Peers
See (EQ) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EQ | $0.38 | +6.39% | 13.6M | -0.97 | -$0.39 | N/A |
| VRTX | $445.85 | -0.14% | 114.5B | -116.41 | -$3.83 | N/A |
| REGN | $484.83 | -0.62% | 51.5B | 12.32 | $39.36 | +0.36% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $305.18 | +0.46% | 39.8B | -145.32 | -$2.10 | N/A |
| ARGX | $573.05 | -0.62% | 35B | 34.98 | $16.38 | N/A |
| BNTX | $111.25 | -3.80% | 26.7B | -30.73 | -$3.62 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| RPRX | $33.44 | +0.45% | 18.8B | 13.65 | $2.45 | +2.56% |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
EQ vs VRTX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, VRTX has a market cap of 114.5B. Regarding current trading prices, EQ is priced at $0.38, while VRTX trades at $445.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas VRTX's P/E ratio is -116.41. In terms of profitability, EQ's ROE is -0.74%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, EQ is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs REGN Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, REGN has a market cap of 51.5B. Regarding current trading prices, EQ is priced at $0.38, while REGN trades at $484.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas REGN's P/E ratio is 12.32. In terms of profitability, EQ's ROE is -0.74%, compared to REGN's ROE of +0.15%. Regarding short-term risk, EQ is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs SGEN Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, EQ is priced at $0.38, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas SGEN's P/E ratio is -57.19. In terms of profitability, EQ's ROE is -0.74%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, EQ is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs ALNY Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ALNY has a market cap of 39.8B. Regarding current trading prices, EQ is priced at $0.38, while ALNY trades at $305.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ALNY's P/E ratio is -145.32. In terms of profitability, EQ's ROE is -0.74%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, EQ is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs ARGX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ARGX has a market cap of 35B. Regarding current trading prices, EQ is priced at $0.38, while ARGX trades at $573.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ARGX's P/E ratio is 34.98. In terms of profitability, EQ's ROE is -0.74%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, EQ is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs BNTX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, BNTX has a market cap of 26.7B. Regarding current trading prices, EQ is priced at $0.38, while BNTX trades at $111.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas BNTX's P/E ratio is -30.73. In terms of profitability, EQ's ROE is -0.74%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, EQ is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs BGNE Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, EQ is priced at $0.38, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas BGNE's P/E ratio is -22.55. In terms of profitability, EQ's ROE is -0.74%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, EQ is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs RPRX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, RPRX has a market cap of 18.8B. Regarding current trading prices, EQ is priced at $0.38, while RPRX trades at $33.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas RPRX's P/E ratio is 13.65. In terms of profitability, EQ's ROE is -0.74%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, EQ is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs DNA-WT Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, EQ is priced at $0.38, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, EQ's ROE is -0.74%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, EQ is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs UTHR Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, UTHR has a market cap of 14.6B. Regarding current trading prices, EQ is priced at $0.38, while UTHR trades at $324.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas UTHR's P/E ratio is 12.92. In terms of profitability, EQ's ROE is -0.74%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, EQ is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs SMMT Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, SMMT has a market cap of 14.4B. Regarding current trading prices, EQ is priced at $0.38, while SMMT trades at $19.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas SMMT's P/E ratio is -57.47. In terms of profitability, EQ's ROE is -0.74%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, EQ is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs GMAB Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, GMAB has a market cap of 13.5B. Regarding current trading prices, EQ is priced at $0.38, while GMAB trades at $21.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas GMAB's P/E ratio is 12.81. In terms of profitability, EQ's ROE is -0.74%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, EQ is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs INCY Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, INCY has a market cap of 13.1B. Regarding current trading prices, EQ is priced at $0.38, while INCY trades at $67.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas INCY's P/E ratio is 337.10. In terms of profitability, EQ's ROE is -0.74%, compared to INCY's ROE of +0.01%. Regarding short-term risk, EQ is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs KRTX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, EQ is priced at $0.38, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas KRTX's P/E ratio is -28.09. In terms of profitability, EQ's ROE is -0.74%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, EQ is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs EXEL Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, EXEL has a market cap of 11.5B. Regarding current trading prices, EQ is priced at $0.38, while EXEL trades at $42.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas EXEL's P/E ratio is 19.27. In terms of profitability, EQ's ROE is -0.74%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, EQ is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs BMRN Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, EQ is priced at $0.38, while BMRN trades at $56.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas BMRN's P/E ratio is 20.77. In terms of profitability, EQ's ROE is -0.74%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, EQ is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs MRNA Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, MRNA has a market cap of 10.5B. Regarding current trading prices, EQ is priced at $0.38, while MRNA trades at $27.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas MRNA's P/E ratio is -3.12. In terms of profitability, EQ's ROE is -0.74%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, EQ is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs ASND Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ASND has a market cap of 10.5B. Regarding current trading prices, EQ is priced at $0.38, while ASND trades at $173.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ASND's P/E ratio is -26.38. In terms of profitability, EQ's ROE is -0.74%, compared to ASND's ROE of +1.91%. Regarding short-term risk, EQ is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs RXDX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, EQ is priced at $0.38, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas RXDX's P/E ratio is -56.47. In terms of profitability, EQ's ROE is -0.74%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, EQ is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs IMGN Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, EQ is priced at $0.38, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas IMGN's P/E ratio is -111.55. In terms of profitability, EQ's ROE is -0.74%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, EQ is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs BPMC Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, BPMC has a market cap of 8.3B. Regarding current trading prices, EQ is priced at $0.38, while BPMC trades at $128.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas BPMC's P/E ratio is -51.03. In terms of profitability, EQ's ROE is -0.74%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, EQ is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs CERE Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, EQ is priced at $0.38, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas CERE's P/E ratio is -16.47. In terms of profitability, EQ's ROE is -0.74%, compared to CERE's ROE of -0.43%. Regarding short-term risk, EQ is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs ROIVW Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, EQ is priced at $0.38, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, EQ's ROE is -0.74%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, EQ is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs TECH Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, TECH has a market cap of 7.8B. Regarding current trading prices, EQ is priced at $0.38, while TECH trades at $49.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas TECH's P/E ratio is 60.07. In terms of profitability, EQ's ROE is -0.74%, compared to TECH's ROE of +0.06%. Regarding short-term risk, EQ is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs ROIV Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ROIV has a market cap of 7.6B. Regarding current trading prices, EQ is priced at $0.38, while ROIV trades at $11.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ROIV's P/E ratio is -14.93. In terms of profitability, EQ's ROE is -0.74%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, EQ is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs RVMD Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, RVMD has a market cap of 7.5B. Regarding current trading prices, EQ is priced at $0.38, while RVMD trades at $40.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas RVMD's P/E ratio is -10.07. In terms of profitability, EQ's ROE is -0.74%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, EQ is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs CORT Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, CORT has a market cap of 7.4B. Regarding current trading prices, EQ is priced at $0.38, while CORT trades at $69.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas CORT's P/E ratio is 60.82. In terms of profitability, EQ's ROE is -0.74%, compared to CORT's ROE of +0.20%. Regarding short-term risk, EQ is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs BBIO Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, BBIO has a market cap of 7.2B. Regarding current trading prices, EQ is priced at $0.38, while BBIO trades at $38.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas BBIO's P/E ratio is -10.68. In terms of profitability, EQ's ROE is -0.74%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, EQ is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs VRNA Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, VRNA has a market cap of 7.1B. Regarding current trading prices, EQ is priced at $0.38, while VRNA trades at $83.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas VRNA's P/E ratio is -41.99. In terms of profitability, EQ's ROE is -0.74%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, EQ is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs JAZZ Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, JAZZ has a market cap of 6.7B. Regarding current trading prices, EQ is priced at $0.38, while JAZZ trades at $109.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas JAZZ's P/E ratio is 14.87. In terms of profitability, EQ's ROE is -0.74%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, EQ is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs HALO Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, HALO has a market cap of 6.6B. Regarding current trading prices, EQ is priced at $0.38, while HALO trades at $53.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas HALO's P/E ratio is 14.32. In terms of profitability, EQ's ROE is -0.74%, compared to HALO's ROE of +1.22%. Regarding short-term risk, EQ is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs RETA Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, EQ is priced at $0.38, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas RETA's P/E ratio is -66.29. In terms of profitability, EQ's ROE is -0.74%, compared to RETA's ROE of +0.47%. Regarding short-term risk, EQ is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs MDGL Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, MDGL has a market cap of 6.2B. Regarding current trading prices, EQ is priced at $0.38, while MDGL trades at $279.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas MDGL's P/E ratio is -15.66. In terms of profitability, EQ's ROE is -0.74%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, EQ is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs TLX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, TLX has a market cap of 5.9B. Regarding current trading prices, EQ is priced at $0.38, while TLX trades at $17.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas TLX's P/E ratio is 195.00. In terms of profitability, EQ's ROE is -0.74%, compared to TLX's ROE of +0.14%. Regarding short-term risk, EQ is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs TGTX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, TGTX has a market cap of 5.9B. Regarding current trading prices, EQ is priced at $0.38, while TGTX trades at $37.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas TGTX's P/E ratio is 148.14. In terms of profitability, EQ's ROE is -0.74%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, EQ is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs IONS Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, IONS has a market cap of 5.6B. Regarding current trading prices, EQ is priced at $0.38, while IONS trades at $35.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas IONS's P/E ratio is -11.73. In terms of profitability, EQ's ROE is -0.74%, compared to IONS's ROE of -0.92%. Regarding short-term risk, EQ is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs ABCM Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, EQ is priced at $0.38, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, EQ's ROE is -0.74%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, EQ is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs NUVL Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, NUVL has a market cap of 5.5B. Regarding current trading prices, EQ is priced at $0.38, while NUVL trades at $76.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas NUVL's P/E ratio is -17.38. In terms of profitability, EQ's ROE is -0.74%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, EQ is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs ISEE Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, EQ is priced at $0.38, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ISEE's P/E ratio is -22.44. In terms of profitability, EQ's ROE is -0.74%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, EQ is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs AXSM Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, AXSM has a market cap of 5.3B. Regarding current trading prices, EQ is priced at $0.38, while AXSM trades at $108.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas AXSM's P/E ratio is -18.74. In terms of profitability, EQ's ROE is -0.74%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, EQ is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs ALKS Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ALKS has a market cap of 5.2B. Regarding current trading prices, EQ is priced at $0.38, while ALKS trades at $31.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ALKS's P/E ratio is 15.02. In terms of profitability, EQ's ROE is -0.74%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, EQ is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs ADMA Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ADMA has a market cap of 4.9B. Regarding current trading prices, EQ is priced at $0.38, while ADMA trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ADMA's P/E ratio is 24.20. In terms of profitability, EQ's ROE is -0.74%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, EQ is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs ALPN Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, EQ is priced at $0.38, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ALPN's P/E ratio is -101.52. In terms of profitability, EQ's ROE is -0.74%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, EQ is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs PCVX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, PCVX has a market cap of 4.4B. Regarding current trading prices, EQ is priced at $0.38, while PCVX trades at $33.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas PCVX's P/E ratio is -8.48. In terms of profitability, EQ's ROE is -0.74%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, EQ is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs AKRO Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, AKRO has a market cap of 4.2B. Regarding current trading prices, EQ is priced at $0.38, while AKRO trades at $53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas AKRO's P/E ratio is -14.14. In terms of profitability, EQ's ROE is -0.74%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, EQ is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs OPT Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, EQ is priced at $0.38, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas OPT's P/E ratio is -1.52. In terms of profitability, EQ's ROE is -0.74%, compared to OPT's ROE of +2.60%. Regarding short-term risk, EQ is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs RNA Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, RNA has a market cap of 4.1B. Regarding current trading prices, EQ is priced at $0.38, while RNA trades at $34.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas RNA's P/E ratio is -11.40. In terms of profitability, EQ's ROE is -0.74%, compared to RNA's ROE of -0.27%. Regarding short-term risk, EQ is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs MRTX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, EQ is priced at $0.38, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas MRTX's P/E ratio is -4.82. In terms of profitability, EQ's ROE is -0.74%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, EQ is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs RYTM Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, RYTM has a market cap of 4.1B. Regarding current trading prices, EQ is priced at $0.38, while RYTM trades at $64.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas RYTM's P/E ratio is -23.00. In terms of profitability, EQ's ROE is -0.74%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, EQ is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs PTCT Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, PTCT has a market cap of 4.1B. Regarding current trading prices, EQ is priced at $0.38, while PTCT trades at $51.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas PTCT's P/E ratio is 7.85. In terms of profitability, EQ's ROE is -0.74%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, EQ is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs MRUS Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, MRUS has a market cap of 4B. Regarding current trading prices, EQ is priced at $0.38, while MRUS trades at $57.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas MRUS's P/E ratio is -13.84. In terms of profitability, EQ's ROE is -0.74%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, EQ is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs ZLAB Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ZLAB has a market cap of 4B. Regarding current trading prices, EQ is priced at $0.38, while ZLAB trades at $36.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ZLAB's P/E ratio is -14.43. In terms of profitability, EQ's ROE is -0.74%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, EQ is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs SRPT Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, SRPT has a market cap of 3.9B. Regarding current trading prices, EQ is priced at $0.38, while SRPT trades at $39.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas SRPT's P/E ratio is -14.99. In terms of profitability, EQ's ROE is -0.74%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, EQ is more volatile compared to SRPT. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs SLNO Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, SLNO has a market cap of 3.9B. Regarding current trading prices, EQ is priced at $0.38, while SLNO trades at $77.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas SLNO's P/E ratio is -16.25. In terms of profitability, EQ's ROE is -0.74%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, EQ is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs CYTK Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, CYTK has a market cap of 3.9B. Regarding current trading prices, EQ is priced at $0.38, while CYTK trades at $32.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas CYTK's P/E ratio is -6.13. In terms of profitability, EQ's ROE is -0.74%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, EQ is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs KRYS Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, KRYS has a market cap of 3.8B. Regarding current trading prices, EQ is priced at $0.38, while KRYS trades at $132.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas KRYS's P/E ratio is 31.68. In terms of profitability, EQ's ROE is -0.74%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, EQ is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs RYZB Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, EQ is priced at $0.38, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas RYZB's P/E ratio is -57.86. In terms of profitability, EQ's ROE is -0.74%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, EQ is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs CBAY Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, EQ is priced at $0.38, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas CBAY's P/E ratio is -32.81. In terms of profitability, EQ's ROE is -0.74%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, EQ is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs ACAD Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, EQ is priced at $0.38, while ACAD trades at $21.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ACAD's P/E ratio is 15.90. In terms of profitability, EQ's ROE is -0.74%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, EQ is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs ACLX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ACLX has a market cap of 3.6B. Regarding current trading prices, EQ is priced at $0.38, while ACLX trades at $65.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ACLX's P/E ratio is -21.90. In terms of profitability, EQ's ROE is -0.74%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, EQ is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs SWTX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, EQ is priced at $0.38, while SWTX trades at $46.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas SWTX's P/E ratio is -13.70. In terms of profitability, EQ's ROE is -0.74%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, EQ is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs RARE Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, RARE has a market cap of 3.5B. Regarding current trading prices, EQ is priced at $0.38, while RARE trades at $36.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas RARE's P/E ratio is -6.28. In terms of profitability, EQ's ROE is -0.74%, compared to RARE's ROE of -1.86%. Regarding short-term risk, EQ is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs CRSP Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, CRSP has a market cap of 3.3B. Regarding current trading prices, EQ is priced at $0.38, while CRSP trades at $38.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas CRSP's P/E ratio is -8.47. In terms of profitability, EQ's ROE is -0.74%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, EQ is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs MLTX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, MLTX has a market cap of 3.2B. Regarding current trading prices, EQ is priced at $0.38, while MLTX trades at $51.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas MLTX's P/E ratio is -22.20. In terms of profitability, EQ's ROE is -0.74%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, EQ is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs PTGX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, PTGX has a market cap of 3.2B. Regarding current trading prices, EQ is priced at $0.38, while PTGX trades at $51.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas PTGX's P/E ratio is 66.06. In terms of profitability, EQ's ROE is -0.74%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, EQ is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs CPRX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, CPRX has a market cap of 3.1B. Regarding current trading prices, EQ is priced at $0.38, while CPRX trades at $25.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas CPRX's P/E ratio is 16.11. In terms of profitability, EQ's ROE is -0.74%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, EQ is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs VKTX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, VKTX has a market cap of 3B. Regarding current trading prices, EQ is priced at $0.38, while VKTX trades at $27.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas VKTX's P/E ratio is -23.28. In terms of profitability, EQ's ROE is -0.74%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, EQ is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs CRNX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, CRNX has a market cap of 3B. Regarding current trading prices, EQ is priced at $0.38, while CRNX trades at $32.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas CRNX's P/E ratio is -8.46. In terms of profitability, EQ's ROE is -0.74%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, EQ is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs MTSR Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, MTSR has a market cap of 3B. Regarding current trading prices, EQ is priced at $0.38, while MTSR trades at $28.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas MTSR's P/E ratio is -11.30. In terms of profitability, EQ's ROE is -0.74%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, EQ is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs SRRK Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, SRRK has a market cap of 2.9B. Regarding current trading prices, EQ is priced at $0.38, while SRRK trades at $30.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas SRRK's P/E ratio is -12.08. In terms of profitability, EQ's ROE is -0.74%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, EQ is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs KYMR Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, KYMR has a market cap of 2.9B. Regarding current trading prices, EQ is priced at $0.38, while KYMR trades at $44.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas KYMR's P/E ratio is -14.23. In terms of profitability, EQ's ROE is -0.74%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, EQ is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs MORF Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, EQ is priced at $0.38, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas MORF's P/E ratio is -14.88. In terms of profitability, EQ's ROE is -0.74%, compared to MORF's ROE of -0.22%. Regarding short-term risk, EQ is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs MOR Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, EQ is priced at $0.38, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas MOR's P/E ratio is -12.64. In terms of profitability, EQ's ROE is -0.74%, compared to MOR's ROE of +2.51%. Regarding short-term risk, EQ is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs LEGN Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, LEGN has a market cap of 2.8B. Regarding current trading prices, EQ is priced at $0.38, while LEGN trades at $30.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas LEGN's P/E ratio is -25.74. In terms of profitability, EQ's ROE is -0.74%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, EQ is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs KDNY Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, EQ is priced at $0.38, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas KDNY's P/E ratio is -12.47. In terms of profitability, EQ's ROE is -0.74%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, EQ is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs MYOV Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, EQ is priced at $0.38, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas MYOV's P/E ratio is -14.05. In terms of profitability, EQ's ROE is -0.74%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, EQ is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs IMVT Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, IMVT has a market cap of 2.6B. Regarding current trading prices, EQ is priced at $0.38, while IMVT trades at $15.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas IMVT's P/E ratio is -5.62. In terms of profitability, EQ's ROE is -0.74%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, EQ is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs IBRX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, IBRX has a market cap of 2.6B. Regarding current trading prices, EQ is priced at $0.38, while IBRX trades at $2.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas IBRX's P/E ratio is -5.13. In terms of profitability, EQ's ROE is -0.74%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, EQ is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs AAPG Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, AAPG has a market cap of 2.6B. Regarding current trading prices, EQ is priced at $0.38, while AAPG trades at $28.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas AAPG's P/E ratio is -38.23. In terms of profitability, EQ's ROE is -0.74%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, EQ is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs PRVB Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, EQ is priced at $0.38, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas PRVB's P/E ratio is -16.43. In terms of profitability, EQ's ROE is -0.74%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, EQ is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs LBPH Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, EQ is priced at $0.38, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas LBPH's P/E ratio is -26.66. In terms of profitability, EQ's ROE is -0.74%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, EQ is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs XENE Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, XENE has a market cap of 2.3B. Regarding current trading prices, EQ is priced at $0.38, while XENE trades at $30.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas XENE's P/E ratio is -9.46. In terms of profitability, EQ's ROE is -0.74%, compared to XENE's ROE of -0.32%. Regarding short-term risk, EQ is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs APLS Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, APLS has a market cap of 2.3B. Regarding current trading prices, EQ is priced at $0.38, while APLS trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas APLS's P/E ratio is -10.28. In terms of profitability, EQ's ROE is -0.74%, compared to APLS's ROE of -1.00%. Regarding short-term risk, EQ is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs ARWR Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, ARWR has a market cap of 2.3B. Regarding current trading prices, EQ is priced at $0.38, while ARWR trades at $16.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas ARWR's P/E ratio is -13.49. In terms of profitability, EQ's ROE is -0.74%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, EQ is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs BCRX Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, BCRX has a market cap of 2.3B. Regarding current trading prices, EQ is priced at $0.38, while BCRX trades at $11.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas BCRX's P/E ratio is -42.40. In terms of profitability, EQ's ROE is -0.74%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, EQ is more volatile compared to BCRX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs DICE Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, EQ is priced at $0.38, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas DICE's P/E ratio is -21.91. In terms of profitability, EQ's ROE is -0.74%, compared to DICE's ROE of +0.56%. Regarding short-term risk, EQ is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs MIRM Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, MIRM has a market cap of 2.2B. Regarding current trading prices, EQ is priced at $0.38, while MIRM trades at $44.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas MIRM's P/E ratio is -27.70. In terms of profitability, EQ's ROE is -0.74%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, EQ is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs NAMSW Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, NAMSW has a market cap of 2.2B. Regarding current trading prices, EQ is priced at $0.38, while NAMSW trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas NAMSW's P/E ratio is N/A. In terms of profitability, EQ's ROE is -0.74%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, EQ is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs NAMS Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, NAMS has a market cap of 2.2B. Regarding current trading prices, EQ is priced at $0.38, while NAMS trades at $19.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas NAMS's P/E ratio is -10.54. In terms of profitability, EQ's ROE is -0.74%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, EQ is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs VCEL Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, VCEL has a market cap of 2.2B. Regarding current trading prices, EQ is priced at $0.38, while VCEL trades at $43.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas VCEL's P/E ratio is 863.40. In terms of profitability, EQ's ROE is -0.74%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, EQ is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs APGE Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, EQ is priced at $0.38, while APGE trades at $36.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas APGE's P/E ratio is -10.11. In terms of profitability, EQ's ROE is -0.74%, compared to APGE's ROE of -0.19%. Regarding short-term risk, EQ is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs CALT Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, EQ is priced at $0.38, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas CALT's P/E ratio is -22.73. In terms of profitability, EQ's ROE is -0.74%, compared to CALT's ROE of -1.67%. Regarding short-term risk, EQ is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs VCYT Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, EQ is priced at $0.38, while VCYT trades at $27.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas VCYT's P/E ratio is 64.98. In terms of profitability, EQ's ROE is -0.74%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, EQ is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs BLTE Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, BLTE has a market cap of 2.1B. Regarding current trading prices, EQ is priced at $0.38, while BLTE trades at $65.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas BLTE's P/E ratio is -47.65. In terms of profitability, EQ's ROE is -0.74%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, EQ is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs KNSA Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, KNSA has a market cap of 2.1B. Regarding current trading prices, EQ is priced at $0.38, while KNSA trades at $28.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas KNSA's P/E ratio is -120.33. In terms of profitability, EQ's ROE is -0.74%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, EQ is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs DNLI Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, DNLI has a market cap of 2.1B. Regarding current trading prices, EQ is priced at $0.38, while DNLI trades at $14.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas DNLI's P/E ratio is -5.40. In terms of profitability, EQ's ROE is -0.74%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, EQ is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs VERA Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, VERA has a market cap of 2B. Regarding current trading prices, EQ is priced at $0.38, while VERA trades at $32.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas VERA's P/E ratio is -10.66. In terms of profitability, EQ's ROE is -0.74%, compared to VERA's ROE of -0.41%. Regarding short-term risk, EQ is less volatile compared to VERA. This indicates potentially lower risk in terms of short-term price fluctuations for EQ.
EQ vs CGON Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, CGON has a market cap of 2B. Regarding current trading prices, EQ is priced at $0.38, while CGON trades at $26.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas CGON's P/E ratio is -17.72. In terms of profitability, EQ's ROE is -0.74%, compared to CGON's ROE of -0.17%. Regarding short-term risk, EQ is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.
EQ vs HRMY Comparison
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 13.6M. In comparison, HRMY has a market cap of 2B. Regarding current trading prices, EQ is priced at $0.38, while HRMY trades at $35.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -0.97, whereas HRMY's P/E ratio is 13.42. In terms of profitability, EQ's ROE is -0.74%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, EQ is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.